SIRAKOSS Osteo3 Gains CE Mark

SIRAKOSS received approval under the CE Mark for Osteo3 nanosynthetic bone graft substitute, intended to fill skeletal voids or gaps on its own or in combination with autograft or allograft.

The company is developing further generations of...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us